[Prediction of the occurrence risk of progressive liver fibrosis in patients with metabolic-associated fatty liver disease based on the SMOTE algorithm and nomogram] [0.03%]
[基于SMOTE算法和nomogram的代谢相关性脂肪型肝病患者进展期肝纤维化发生风险预测]
Y L Luo,X L Gao,J Z Wang et al.
Y L Luo et al.
Objective: To explore the occurrence of risk factors, construct a nomogram, and evaluate its predictive value for progressive liver fibrosis (PLF) in patients with metabolic-associated fatty liver disease (MAFLD). Methods: The clinical data...
[Advances in research on metabolic associated fatty liver disease in 2025] [0.03%]
2025年代谢相关脂肪性肝病研究进展
H Y Rao,J M Zhao,C H Yu et al.
H Y Rao et al.
[Advances in basic and experimental diagnostic research on liver diseases in 2025] [0.03%]
2025年肝病诊断基础与实验研究进展
D B Chen,R F Yang,H S Chen
D B Chen
[A case of toxic shock syndrome secondary to severe bone marrow suppression induced by azathioprine in a patient with autoimmune hepatitis] [0.03%]
[一例硫唑嘌呤所致重度骨髓抑制继发毒血症综合征的病例分析]
Y Ren,M Kong,C Y Huang et al.
Y Ren et al.
[Impact of key indicator dynamic change on 90-day prognosis for patients with acute-on-chronic liver failure] [0.03%]
急性肝衰竭关键指标动态变化对90天预后的价值分析
W L Wang,M M Xu,Y Wu et al.
W L Wang et al.
Objective: To compare and analyze the impact of key indicator dynamic change on the 90-day prognosis of patients who remain in a state of acute-on-chronic liver failure (ACLF) at 28 days so as to provide new evidence for individualized trea...
[Clinical analysis of blood ammonia levels for predicting survival following transjugular intrahepatic portosystemic shunt in patients with cirrhosis] [0.03%]
血氨水平对肝硬化患者经颈静脉肝内门体分流术预后的临床分析
Y Liu,F Zhang,Q Yin et al.
Y Liu et al.
Objective: To assess the blood ammonia levels value for predicting survival following transjugular intrahepatic portosystemic shunt (TIPS) therapy in patients with cirrhosis. Methods: Data from 236 cirrhotic patients who underwent TIPS trea...
[Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B] [0.03%]
替比夫定或拉米夫定单药与联合干扰素α治疗1-6岁乙肝e抗原阳性慢性乙型肝炎患儿的疗效比较
Z W Wang,Y Dong,W X Ouyang et al.
Z W Wang et al.
Objective: To explore the antiviral efficacy and safety profile of nucleos(t)ide analogue (NA) mono-or combination therapy with interferon-α (IFN-α) in children 1-6 years old with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B...
[Towards precision diagnosis and treatment: interpretation of the ten highlights of the expert consensus on the diagnosis and treatment of hereditary hyperbilirubinemia (version 2025)] [0.03%]
向精准诊断与治疗迈进——遗传性高胆红素血症诊治专家共识（2025年版）十问解读
W Hou,Z P Duan,S J Zheng
W Hou
To assist relevant clinicians specializing in liver diseases in making informed decisions regarding the diagnosis and treatment of hereditary hyperbilirubinemia, the Inherited and Metabolic Liver Disease Cooperative Group of the Hepatology ...
[Expert consensus on the diagnosis, treatment, and management of liver nodules (version 2026)] [0.03%]
[肝结节的诊断、治疗和管理专家共识（2026版）]
Infectious Diseases Prevention and Control Branch, Chinese Preventive Medicine Association
Infectious Diseases Prevention and Control Branch
Liver nodules are one of the common and complex clinical conditions, with certain ones developing into malignant lesions, hence significantly affecting patient prognosis. The detection rate of liver nodules has significantly improved with a...